2001
Insulin-like growth factor-I and prostate cancer: a meta-analysis
Shi R, Berkel H, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. British Journal Of Cancer 2001, 85: 991-996. PMID: 11592771, PMCID: PMC2375097, DOI: 10.1054/bjoc.2001.1961.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceLevels of IGFProstate cancer patientsStandardized mean differenceIGFBP-3Prostate cancerHigher IGFCancer patientsInsulin-like growth factorIGF-binding proteinsEffects of IGFCase-control studyLow IGFMEDLINE searchIGFMean differenceGrowth factorCancerPatientsStandard protocolRiskLevelsLevels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence
Yu H, Nicar M, Shi R, Berkel H, Nam R, Trachtenberg J, Diamandis E. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001, 57: 471-475. PMID: 11248622, DOI: 10.1016/s0090-4295(00)01003-7.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCase-Control StudiesDisease ProgressionEnzyme-Linked Immunosorbent AssayHumansInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualProstate-Specific AntigenProstatic NeoplasmsConceptsPostoperative serum samplesInsulin-like growth factor IIGFBP-3IGFBP-2Growth factor IProstate cancerSerum levelsSerum samplesFactor IIGFBP-2 levelsIGFBP-3 levelsIGF-I levelsGroup of patientsLow serum levelsProstate cancer patientsProstate cancer recurrenceProtein 2Recurrent diseaseDisease recurrenceMedian timePrognostic valueCancer patientsRadical prostatectomyCancer recurrenceSerum collection
2000
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up
Vassilikos E, Yu H, Trachtenberg J, Nam R, Narod S, Bromberg I, Diamandis E. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clinical Biochemistry 2000, 33: 115-123. PMID: 10751589, DOI: 10.1016/s0009-9120(99)00099-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease-Free SurvivalFluorescent Antibody TechniqueFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsProstate-Specific AntigenProstatectomyProstatic NeoplasmsRecurrenceRegression AnalysisReproducibility of ResultsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsProstate cancer patientsRadical prostatectomySerum PSACancer patientsPSA assaysUltrasensitive prostate specific antigenPre-operative PSAGroup of patientsSerial serum samplesEarly therapeutic interventionSeminal vesicle invasionSurgical margin positivityProstate-specific antigenRegular PSAUltrasensitive PSAPSA increaseMargin positivityClinical stageGleason scorePrognostic indicatorCapsular invasionTissue involvementTumor volumePatientsFast relapseComparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy
Scorilas A, Yu H, Soosaipillai A, Gregorakis A, Diamandis E. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clinica Chimica Acta 2000, 292: 127-138. PMID: 10686282, DOI: 10.1016/s0009-8981(99)00211-9.Peer-Reviewed Original ResearchConceptsPercent free PSAProstate cancer patientsFree PSAProstate cancerCancer patientsRadical prostatectomyPercent free prostate-specific antigen levelsCancer aggressivenessFree prostate specific antigen levelsProstate-specific antigen levelProstate cancer screening programsAge-matched menCancer screening programsRecurrent prostate cancerBenign prostatic hyperplasiaProstate cancer aggressivenessAntigen levelsTotal PSAGleason scoreHealthy menProstatic hyperplasiaProstatic diseaseScreening programPatientsPathological indicators
1995
Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique
Zarghami N, Yu H, Diamandis E, Sutherland D. Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. Clinical Biochemistry 1995, 28: 243-253. PMID: 7554242, DOI: 10.1016/0009-9120(95)00010-7.Peer-Reviewed Original ResearchConceptsCK-BB levelsBreast tumor cytosolsCreatine kinase BBCK-BBProstate cancerTumor cytosolsCancer patientsEstrogen sensitivityHealthy subjectsSerum CK-BB levelsActive prostate cancerSensitive immunofluorometric procedurePost-radical prostatectomyProstate cancer patientsSerum CK-BBCK-BB isoenzymeSteroid hormone receptorsSerum PSAProgesterone receptorRadical prostatectomyBreast cancerMale volunteersHealthy volunteersPatientsBreast tumorsUltrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy.
Yu H, Diamandis E, Prestigiacomo A, Stamey T. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clinical Chemistry 1995, 41: 430-434. PMID: 7533672, DOI: 10.1093/clinchem/41.3.430.Peer-Reviewed Original ResearchConceptsTumor-doubling timeProstate-specific antigenProstate cancer relapseRelapse-free periodRadical prostatectomyPSA assaysCancer relapseUltrasensitive prostate specific antigenProstate cancer patientsUltrasensitive assayExponential tumor growthPSA changeCancer patientsPatientsProstatectomyTumor growthEarly detectionRelapseAntigenAssaysBasis of criteriaDaysCystoprostatectomyPostsurgerySurgeryOriginal Articles
Yu H, Diamandis E. Original Articles. Journal Of Urology 1995, 153: 1004-1008.. DOI: 10.1097/00005392-199503000-00026.Peer-Reviewed Original ResearchSerum prostate-specific antigenProstate-specific antigenPSA levelsDetectable serum prostate specific antigenDistribution of PSAHigher serum prostate-specific antigenHealthy female blood donorsMeasurable prostate-specific antigenPostoperative prostate-specific antigenPreoperative prostate-specific antigenYear of surgeryEvidence of relapseFemale blood donorsAge 50 yearsProstate cancer patientsHospitalized womenPatients 50Recurrent tumorsHistological gradeCancer patientsRadical prostatectomyBlood donorsSpecific antigenFemale serumMicrogramsOriginal Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique
Yu H, Diamandis E. Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique. Journal Of Urology 1995, 153: 1004-1008. PMID: 7531781, DOI: 10.1016/s0022-5347(01)67622-5.Peer-Reviewed Original ResearchConceptsSerum prostate-specific antigenProstate-specific antigenPSA levelsDetectable serum prostate specific antigenDistribution of PSAHigher serum prostate-specific antigenSerum prostate-specific antigen levelHealthy female blood donorsMeasurable prostate-specific antigenPostoperative prostate-specific antigenPreoperative prostate-specific antigenProstate-specific antigen levelYear of surgeryEvidence of relapseFemale blood donorsSpecific antigen levelsAge 50 yearsProstate cancer patientsHospitalized womenPatients 50Recurrent tumorsAntigen levelsHistological gradeCancer patientsRadical prostatectomy